Cargando…

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

PURPOSE: The phase I study characterized the safety, pharmacokinetics, anti-tumor activity, and recommended phase II dose/schedule of LY3164530 in patients with advanced or metastatic cancer. METHODS: Patients received LY3164530 on days 1 and 15 (Schedule 1: 300, 600, 1000, and 1250 mg) or Days 1, 8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patnaik, Amita, Gordon, Michael, Tsai, Frank, Papadopoulous, Kyri, Rasco, Drew, Beeram, S. Muralidhar, Fu, Siqing, Janku, Filip, Hynes, Scott M., Gundala, Sushma R., Willard, Melinda D., Zhang, Wei, Lin, Aimee Bence, Hong, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105165/ https://www.ncbi.nlm.nih.gov/pubmed/29926131 http://dx.doi.org/10.1007/s00280-018-3623-7

Ejemplares similares

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer
por: Goldman, Jonathan W., et al.
Publicado: (2017)

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
por: Patnaik, Amita, et al.
Publicado: (2021)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020)

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
por: Laquente, Berta, et al.
Publicado: (2017)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
por: Wang, Peiyin, et al.
Publicado: (2022)

A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors
por: Patnaik, Amita, et al.
Publicado: (2022)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
por: Yuan, Qingyun, et al.
Publicado: (2021)

A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
por: Sun, Zu-Jun, et al.
Publicado: (2017)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome
por: Luo, Linlin, et al.
Publicado: (2016)

A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
por: Perez Bay, Andres E., et al.
Publicado: (2023)

Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma
por: Jiang, Wei, et al.
Publicado: (2021)

Developmental and communicative interrelations of Ly123 and Ly1 cell sets
Publicado: (1980)

Neces-SARI-ly?
por: Martin-Loeches, Ignacio, et al.
Publicado: (2016)

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
por: Hong, David S., et al.
Publicado: (2015)

Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody
por: Jarantow, Stephen W., et al.
Publicado: (2015)

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

Running Mad-ly into mitosis
por: LeBrasseur, Nicole
Publicado: (2004)

Virulence profile: Hinh Ly
por: Ly, Hinh
Publicado: (2016)

Comparison of Mouse Ly5(a) and Ly5(b) Leucocyte Common Antigen Alleles
por: Zebedee, Suzanne L., et al.
Publicado: (1991)

Secretion of Ia antigens by a subpopulation of T cells which are Ly-1+, Ly-2-, and Ia-
Publicado: (1976)

Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules
por: Datta-Mannan, Amita, et al.
Publicado: (2021)

Tiritiria: Understanding Māori children as inherently and inherited-ly literate—Towards a conceptual position
por: Hetaraka, Maia, et al.
Publicado: (2023)

Fractured T Tube Fragment in Common Bile Duct during Retrieval: An Unforeseen Mishap
por: Rajput, Deepak, et al.
Publicado: (2021)

Expression of Ly 1, Ly 2, Thy 1, and TL differentiation antigens on mouse T-cell tumors
Publicado: (1978)

Occurrences and Functions of Ly6C(hi) and Ly6C(lo) Macrophages in Health and Disease
por: Li, Yuan-hui, et al.
Publicado: (2022)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
por: Zauderer, Marjorie G., et al.
Publicado: (2021)

SLEEPLESS, a Ly–6/Neurotoxin Family Member, Regulates Levels, Localization, and Activity of Shaker
por: Wu, Mark N., et al.
Publicado: (2009)

Models of Ly$\alpha$ forest clouds
por: Charlton, J C
Publicado: (1995)

Role of Ly-6 in lymphocyte activation. II. Induction of T cell activation by monoclonal anti-Ly-6 antibodies
Publicado: (1986)

Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
por: Wu, Daichao, et al.
Publicado: (2016)

A novel isoform of the Ly108 gene ameliorates murine lupus
por: Keszei, Marton, et al.
Publicado: (2011)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

BEAT(® )the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs
por: Moretti, Pierre, et al.
Publicado: (2013)

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
por: Tolcher, Anthony W., et al.
Publicado: (2013)

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity
por: Castoldi, R, et al.
Publicado: (2013)

Splenic Ly6G(high) mature and Ly6G(int) immature neutrophils contribute to eradication of S. pneumoniae
por: Deniset, Justin F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8efh5m5m97agkbc7rmjiotfo01